Grifols (GRFS) Change in Acquisitions & Divestments (2010 - 2016)
Grifols' (GRFS) quarterly Change in Acquisitions & Divestments came in at $8.7 million in Q4 2016, up 147.47% YoY from $3.5 million in Q1 2016, and up 148.49% on a QoQ basis from -$18.0 million in Q3 2016.
Grifols (GRFS) Change in Acquisitions & Divestments (2010 - 2016) Analysis & Trends
Grifols (GRFS) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $8.7 million in Q4 2016.
- Quarterly Change in Acquisitions & Divestments rose 147.47% year-over-year to $8.7 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$19.8 million (down 15425.5% YoY) and the FY2021 annual result came in at $969.3 million, up 312001.28% from the prior year.
- Change in Acquisitions & Divestments improved to $8.7 million in Q4 2016, from -$18.0 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $109.0 million in Q2 2012 to a low of -$18.4 million in Q4 2015.
- A 5-year average of $8.8 million and a median of $2.5 million in 2013 frame the typical range for Change in Acquisitions & Divestments.
- Annual changes were most pronounced in 2012 — Change in Acquisitions & Divestments jumped 6514.2% — and 2016, when it sank 329.4%.
- Tracing GRFS's Change in Acquisitions & Divestments over 5 years: stood at -$2.3 million in 2012, then soared by 642.38% to $12.4 million in 2013, then tumbled by 176.09% to -$9.4 million in 2014, then tumbled by 95.28% to -$18.4 million in 2015, then soared by 147.47% to $8.7 million in 2016.
- The last three Change in Acquisitions & Divestments figures came in at $8.7 million (Q4 2016), -$18.0 million (Q3 2016), and -$18.4 million (Q4 2015), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 8.71 Mn |
| Dec 31, 2016 | 8.71 Mn |
| Sep 30, 2016 | -17.97 Mn |
| Sep 30, 2016 | -17.97 Mn |
| Dec 31, 2015 | -18.35 Mn |
| Dec 31, 2015 | -18.35 Mn |
| Sep 30, 2015 | 7.83 Mn |
| Sep 30, 2015 | 7.83 Mn |
| Jun 30, 2015 | 14.68 Mn |
| Jun 30, 2015 | 14.68 Mn |
| Mar 31, 2015 | -4.03 Mn |
| Mar 31, 2015 | -4.03 Mn |
| Dec 31, 2014 | -9.40 Mn |
| Dec 31, 2014 | -9.40 Mn |
| Sep 30, 2014 | 10.00 Mn |
| Sep 30, 2014 | 10.00 Mn |
| Jun 30, 2014 | -2.51 Mn |
| Jun 30, 2014 | -2.51 Mn |
| Mar 31, 2014 | 2.51 Mn |
| Mar 31, 2014 | 2.51 Mn |